Latest News and Blogs > 

BiologIC`s Richard Vellacott talks to Cambridge 105's Ian Daborn about synthetic biology and how BiologIC will unlock its exciting potential using Industry 4.0 technologies. To hear the full intervie...

Stratasys hosts BiologIC’s Richard Vellacott to discuss industry 4.0 and the 2nd wave of additive manufacturing. Hosted by Zehavit Reisin VP,EMEA and NASA Head of solutions and material business. To...

EXECUTIVE INTERVIEW – BiologIC Technologies: The Future Microsoft for the Biorevolution The following article appeared in Drug Development and Delivery   BiologIC Technologies is a world leader in ...

BiologIC’s pioneering digital architectures for radically different automation in synthetic biology deploy the latest developments in 3D printing technology. ...

Biology has incredible potential to benefit society, but the scale up phase is severely constrained.  To unlock this disruptive value, we need to complete the Holy Trinity of digital software, wetware...

Life sciences is stuck in a rut.  Whilst we are making incredible strides in discovering new bioproducts enabled by our ability to “read DNA” and “write DNA”, we are only just beginning to “apply DNA”...

Synthetic biology is the field where the twin disciplines of technology and biology meet.  Since the sequencing of the first human genome in the early 2000s, the first wave of synbio, our ability to “...

BiologIC is hugely excited about Advanced Therapies (ATs) and we see a new era of medicine enabled by these therapies. One opportunity in this new era is the model of delivery of therapies to patien...

BiologIC’s factory-in-a-box means faster, cheaper cures Cambridge Independent By Mike Scialom mike.scialom@iliffemedia.co.uk Published: 08:53, 29 November 2019 Updated: 10:30, 29 November 2019 B...

We recently had a very exciting meeting with our EnterpriseTECH team to explore the different commercialisation opportunities for our technology. Getting a new business up and running is a busy time ...

Advanced Therapies (ATs) are a hugely exciting area of medicine although the very first regulatory cleared ATs have significant cost of goods. Decentralised manufacturing of these therapies – potentia...